Skip to main
TEVA

Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Teva Pharmaceutical (TEVA) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Teva Pharmaceutical Indus is well positioned for growth, with recent acquisitions and a strong focus on developing innovative treatments, including a potential blockbuster drug for vitiligo and celiac disease. Analysts recommend overweighting the stock due to its strong pipeline and potential for significant sales growth. Additionally, Teva's recent earnings report showed strong performance and a focus on incremental innovation, which could lead to increased cash flow and strategic investments in the future.

Bears say

Teva Pharmaceutical Indus is facing headwinds in its pediatric Tourette portfolio acquisition, leading to slow script growth and delayed revenue recognition. The company's disciplined BD approach and focus on neuroscience and rare diseases could lead to future deals in the low-hundreds-of-millions range, but potential impairments of goodwill could impact financials in the coming quarters.

Teva Pharmaceutical (TEVA) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teva Pharmaceutical (TEVA) Forecast

Analysts have given Teva Pharmaceutical (TEVA) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Teva Pharmaceutical (TEVA) has a Strong Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teva Pharmaceutical (TEVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.